Filing Details
- Accession Number:
- 0001209191-23-033392
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-01 17:42:09
- Reporting Period:
- 2023-05-30
- Accepted Time:
- 2023-06-01 17:42:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 949858 | Achieve Life Sciences Inc. | ACHV | In Vitro & In Vivo Diagnostic Substances (2835) | 954343413 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1477056 | John Bencich | 22722 29Th Dr Se Suite 100 Bothell WA 98021 | Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-30 | 5,000 | $5.50 | 66,730 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Footnotes
- The shares reported on this Form 4 were purchased in a registered direct offering at a price of $5.50 per share, for an aggregate purchase price of $27,500, pursuant to a Securities Purchase Agreement dated May 25, 2023.
Billionaire Hedge Funds
